Evidence map›Paper›PMID 26553670›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.

Lionel Martellet, Samba O Sow, Aldiouma Diallo, Abraham Hodgson, Beate Kampmann, Siddhivinayak Hirve, Milagritos Tapia, Fadima Cheick Haidara, Assane Ndiaye, Bou Diarra and 15 more

Abstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. New ethical considerations in vaccine trials.Human vaccines & immunotherapeutics · 2017
    Article
  5. Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lionel MartelletMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Samba O SowCentre pour le Développement des Vaccins, Bamako, Mali.
Aldiouma DialloInstitut pour la Recherche et le Développement, Niakhar, Senegal.
Abraham HodgsonNavrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
Beate KampmannVaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
Siddhivinayak HirveShirdi Sai Baba Hospital, Vadu/King Edward Memorial Hospital Research Centre, Rasta Peth, Pune, India.
Milagritos TapiaDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
Fadima Cheick HaidaraCentre pour le Développement des Vaccins, Bamako, Mali.
Assane NdiayeInstitut pour la Recherche et le Développement, Niakhar, Senegal.
Bou DiarraInstitut pour la Recherche et le Développement, Niakhar, Senegal.
Patrick Odum AnsahNavrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
Adebayo AkinsolaVaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
Olubukola T IdokoVaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
Richard A AdegbolaGlaxoSmithKline Vaccines, Wavre, Belgium.
Ashish BavdekarShirdi Sai Baba Hospital, Vadu/King Edward Memorial Hospital Research Centre, Rasta Peth, Pune, India.
Sanjay JuvekarShirdi Sai Baba Hospital, Vadu/King Edward Memorial Hospital Research Centre, Rasta Peth, Pune, India.
Simonetta VivianiMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Godwin C EnwereMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Elisa MarchettiMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Julie ChaumontMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Marie-Francoise MakadiMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Flore PallardyMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Prasad S KulkarniSerum Institute of India, Ltd, Pune.
Marie-Pierre PreziosiMeningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
F Marc LaForceSerum Institute of India, Ltd, Pune.

Funding

Medical Research Council MC_EX_MR/K011944/1Medical Research Council MC_UP_A900_1122World Health Organization 001
6 · The paper itself

Abstract

backgroundThe group A meningococcal vaccine (PsA-TT) clinical development plan included clinical trials in India and in the West African region between 2005 and 2013. During this period, the Meningitis Vaccine Project (MVP) accumulated substantial experience in the ethical conduct of research to the highest standards.

methodsBecause of the public-private nature of the sponsorship of these trials and the extensive international collaboration with partners from a diverse setting of countries, the ethical review process was complex and required strategic, timely, and attentive communication to ensure the smooth review and approval for the clinical studies. Investigators and their site teams fostered strong community relationships prior to, during, and after the studies to ensure the involvement and the ownership of the research by the participating populations. As the clinical work proceeded, investigators and sponsors responded to specific questions of informed consent, pregnancy testing, healthcare, disease prevention, and posttrial access.

resultsKey factors that led to success included (1) constant dialogue between partners to explore and answer all ethical questions; (2) alertness and preparedness for emerging ethical questions during the research and in the context of evolving international ethics standards; and (3) care to assure that approaches were acceptable in the diverse community contexts.

conclusionsMany of the ethical issues encountered during the PsA-TT clinical development are familiar to groups conducting field trials in different cultural settings. The successful approaches used by the MVP clinical team offer useful examples of how these problems were resolved. CLINICAL TRIALS REGISTRATION: ISRCTN17662153 (PsA-TT-001); ISRTCN78147026 (PsA-TT-002); ISRCTN87739946 (PsA-TT-003); ISRCTN46335400 (PsA-TT-003a); ISRCTN82484612 (PsA-TT-004); CTRI/2009/091/000368 (PsA-TT-005); PACTR ATMR2010030001913177 (PsA-TT-006); PACTR201110000328305 (PsA-TT-007).

Indexed as

Africa, WesternClinical Trials as TopicHumansIndiaInternational CooperationMeningococcal VaccinesPublic-Private Sector PartnershipsVaccinationMenAfriVacMeningococcal Vaccinesdeveloping countriesethicsethics committeesinformed consentsubject protection

Identifiers

PMID26553670
PMCPMC4639500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.